New York, NY (PRWEB) May 09, 2016
The innovative Eeva® Test brings insight and accuracy to the fertility clinic lab, arming embryologists with a non-invasive predictive test designed to aid in the assessment of embryos during an in vitro fertilization procedure. Based on landmark research conducted at Stanford University, the Eeva Test uses time-lapse imaging data to consistently and objectively access early embryo development milestones without disturbing the embryos during incubation.
This new agreement allows for extended distribution of the Eeva Test software. Further, this agreement allows for the Eeva Test to be sold as a software only platform opening up new possibilities for collaborations in the non-invasive embryo assessment field.
About Progyny:
Progyny is a best-in-class health care company providing consumers effective fertility outcomes by aligning science, technology, clinics and patients. Offering unique fertility solutions to consumers, employers and health plans, Progyny is the first company with a cost-effective fertility benefit product to better manage women’s fertility while reducing high maternity and NICU-related costs. Progyny’s portfolio of solutions includes: Progyny Fertility Benefits - the first cost-efficient fertility benefit solution for employers and health plans, FertilityAuthority.com, the country’s leading patient-matching technology platform serving the fertility industry; EggBanxx.com, a national network of hundreds of top fertility doctors specializing in egg freezing; IVFAdvantage.com, the only multi-cycle IVF savings program created by patients for patients; and The Eeva™ Test, the first and only FDA-cleared test to aid in embryo selection. Progyny is privately held and its investors include Kleiner Perkins Caufield & Byers, TPG Biotech, SR One and MS Ventures. The company is headquartered in New York, NY, with operations in Menlo Park, CA. For more information, please visit https://www.progyny.com.
About the Eeva Test:
The non-invasive Early Embryo Viability Assessment (Eeva®) Test, when used adjunctively with traditional morphology, may improve IVF outcomes by providing IVF clinicians and patients with objective information on embryo viability. The Eeva System utilizes proprietary software that automatically analyzes embryo development against scientifically and clinically validated parameters. With Eeva’s quantitative data on each embryo’s potential development, IVF clinicians can enhance the treatment path for their patients undergoing IVF procedures.
About Merck KGaA, Darmstadt, Germany:
Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck KGaA, Darmstadt, Germany, generated sales of € 12.85 billion in 66 countries.
Founded in 1668, Merck KGaA, Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck KGaA, Darmstadt, Germany, holds the global rights to the Merck KGaA, Darmstadt, Germany, name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.